Jin Zheng, Liu Jiali, Guo Sihan, Xu Shangen, Gong Xiaochen, Zhang Chunjing, Zhao Kai
Zhejiang Provincial Key Laboratory of Plant Evolutionary Ecology and Conservation, Taizhou Key Laboratory of Biomedicine and Advanced Dosage Forms, School of Life Sciences, Taizhou University, Taizhou, Zhejiang, 318000, People's Republic of China.
Engineering Research Center of Agricultural Microbiology Technology, Ministry of Education, Heilongjiang University, Harbin 150080, China; Key Laboratory of Microbiology, College of Heilongjiang Province, School of Life Sciences, Heilongjiang University, Harbin, Heilongjiang, 150080, People's Republic of China.
Int J Nanomedicine. 2025 Jan 31;20:1321-1334. doi: 10.2147/IJN.S496077. eCollection 2025.
Porcine epidemic diarrhea virus (PEDV) inactivated vaccine lacks an effective vaccine adjuvant as an immune activator. The aim of this study was to develop N-2-HACC-Al nano-adjuvant as a high immune-enhancing adjuvant and to make the vaccine suitable for intramuscular and oral administration.
N-2-HACC-Al nano-adjuvant was prepared by ion crosslinking method using the N-2-hydroxypropyl trimethyl ammonium chloride chitosan (N-2-HACC). The N-2-HACC-Al nano-adjuvant was characterised, and its safety was determined by analysing the cytotoxicity and hemolysis. PED inactivated vaccine (N-2-HACC-Al/PEDV) was prepared by electrostatic adsorption method, and mice were inoculated by intramural injection and orally to evaluate the immune enhancement effect and application potential of the N-2-HACC-Al/PEDV.
The hemolysis rate was 3.89 ± 0.12% and the activity of PK15 cells was 77.40 ± 1.74%, indicating that the N-2-HACC-Al/PEDV had good biosafety. The levels of PEDV antibodies induced by the N-2-HACC-Al/PEDV were higher than those of commercially available vaccines, both by intramural injection and oral administration. Except for the serum IgG1 levels in the N-2-HACC-Al/PEDV injection group, which were similar to those in the commercial PEDV group, the serum IgG1, IgG2a, IgG2c and sIgA levels in the injection, and the oral groups were significantly higher than those in the commercial group. These results indicated and that N-2-HACC-Al nano-adjuvant significantly enhanced cellular immunity and N-2-HACC-Al nano-adjuvant could deliver PEDV antigen across the mucosal layer of the intestine and induced a strong mucosal immune response.
N-2-HACC-Al nano-adjuvant is safe and can efficiently induce humoral, cellular and mucosal immunity efficiently, which provides a new idea for the development of oral mucosal vaccine adjuvant.
猪流行性腹泻病毒(PEDV)灭活疫苗缺乏有效的疫苗佐剂作为免疫激活剂。本研究的目的是开发N-2-HACC-Al纳米佐剂作为一种高效免疫增强佐剂,并使疫苗适用于肌肉注射和口服。
采用N-2-羟丙基三甲基氯化铵壳聚糖(N-2-HACC)通过离子交联法制备N-2-HACC-Al纳米佐剂。对N-2-HACC-Al纳米佐剂进行表征,并通过分析细胞毒性和溶血作用来确定其安全性。通过静电吸附法制备PED灭活疫苗(N-2-HACC-Al/PEDV),并通过肌肉内注射和口服接种小鼠,以评估N-2-HACC-Al/PEDV的免疫增强效果和应用潜力。
溶血率为3.89±0.12%,PK15细胞活性为77.40±1.74%,表明N-2-HACC-Al/PEDV具有良好的生物安全性。通过肌肉内注射和口服,N-2-HACC-Al/PEDV诱导的PEDV抗体水平均高于市售疫苗。除N-2-HACC-Al/PEDV注射组的血清IgG1水平与市售PEDV组相似外,注射组和口服组的血清IgG1、IgG2a、IgG2c和sIgA水平均显著高于市售组。这些结果表明,N-2-HACC-Al纳米佐剂显著增强了细胞免疫,并且N-2-HACC-Al纳米佐剂可以将PEDV抗原递送至肠道粘膜层并诱导强烈的粘膜免疫反应。
N-2-HACC-Al纳米佐剂安全且能有效诱导体液免疫、细胞免疫和粘膜免疫,为口服粘膜疫苗佐剂的开发提供了新思路。